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Abstract 
Background: Over 1.6 million adolescents in the United States meet criteria for substance use disorders (SUDs). 
While there are promising treatments for SUDs, adolescents respond to these treatments differentially in part based 
on the setting in which treatments are delivered. One way to address such individualized response to treatment is 
through the development of adaptive interventions (AIs): sequences of decision rules for altering treatment based 
on an individual’s needs. This protocol describes a project with the overarching goal of beginning the development 
of AIs that provide recommendations for altering the setting of an adolescent’s substance use treatment. This project 
has three discrete aims: (1) explore the views of various stakeholders (parents, providers, policymakers, and research-
ers) on deciding the setting of substance use treatment for an adolescent based on individualized need, (2) generate 
hypotheses concerning candidate AIs, and (3) compare the relative effectiveness among candidate AIs and non-adap-
tive interventions commonly used in everyday practice.
Methods: This project uses a mixed-methods approach. First, we will conduct an iterative stakeholder engagement 
process, using RAND’s ExpertLens online system, to assess the importance of considering specific individual needs 
and clinical outcomes when deciding the setting for an adolescent’s substance use treatment. Second, we will use 
results from the stakeholder engagement process to analyze an observational longitudinal data set of 15,656 ado-
lescents in substance use treatment, supported by the Substance Abuse and Mental Health Services Administration, 
using the Global Appraisal of Individual Needs questionnaire. We will utilize methods based on Q-learning regression 
to generate hypotheses about candidate AIs. Third, we will use robust statistical methods that aim to appropriately 
handle casemix adjustment on a large number of covariates (marginal structural modeling and inverse probability of 
treatment weights) to compare the relative effectiveness among candidate AIs and non-adaptive decision rules that 
are commonly used in everyday practice.
Discussion: This project begins filling a major gap in clinical and research efforts for adolescents in substance use 
treatment. Findings could be used to inform the further development and revision of influential multi-dimensional 
assessment and treatment planning tools, or lay the foundation for subsequent experiments to further develop or test 
AIs for treatment planning.
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Background
Over 6% of all 12–17 year olds (or 1.6 million youth) meet 
criteria for a substance use disorder (SUD) [1]. SUDs can 
lead to immediate and long-term effects for adolescents, 
such as poor school performance, school drop-out and 
delinquency, future health problems, motor vehicle acci-
dents, unintentional injuries, and suicide [2–5]. Although 
many adolescents with SUDs receiving treatment 
improve in the short-term, the vast majority continue to 
use or experience substance-related consequences within 
6–12 months of discharge [7–11], while a large percent-
age dropout from treatment prior to finishing a particu-
lar treatment episode [12, 13].
Adolescents respond to treatment differentially in part 
based on the treatment setting: that is, whether care is 
received in outpatient, intensive outpatient, inpatient, or 
residential settings [6, 14–17]. A sequential, individual-
ized approach to making decisions about substance use 
treatment aims to address heterogeneity in responses 
to treatment across adolescents as well as for the same 
adolescent over time [15, 18, 19]. In this approach, treat-
ment providers make decisions about (1) what treatment 
to provide initially, (2) how best to monitor response to 
treatment, and (3) whether or how best to alter treat-
ment [20–22]. There is currently little empirical research 
on which settings to offer treatment, at what stages in 
the clinical pathway, based on what kind of treatment 
response, measured using which variables—and little 
guidance on such sequential decision-making as a result. 
Thus, addiction science and clinical practice would ben-
efit from empirically-based guidance for altering treat-
ment setting of adolescents with SUDs.
Adaptive interventions for adolescent substance use 
treatment settings
Adaptive interventions (AIs)—also known as adaptive 
treatment strategies, treatment algorithms, or dynamic 
treatment regimens—assist sequential, individualized 
decision-making by recommending whether, how, or 
when to alter treatment for an individual at critical deci-
sion points [23–25]. While AIs can be developed for 
clinical treatments or adherence interventions [26, 27], 
this project focuses specifically on developing AIs for 
adolescent substance use treatment settings: i.e., well-
operationalized, empirically-supported recommenda-
tions to consider when making individualized, sequential 
decisions about which treatment setting an adolescent 
with an SUD should receive treatment, based on their 
individual needs. These AIs will be composed of (1) 
critical decision stages (i.e., 3-month intervals), (2) set-
ting options, (3) tailoring variables and outcomes used 
to make decisions concerning which service to provide, 
and (4) replicable decision rules linking treatment setting 
recommendations, responses to tailoring variables, and 
desired outcomes. These AIs can assist families, provid-
ers, and policymakers in deciding on treatment settings 
for adolescent clients at multiple stages over time.
As an example, consider the AI shown in Fig. 1. There 
are two decision points: stage 1 concerns which service 
to recommend for months 0–3, and stage 2 concerns 
which service to recommend during months 3–6. In this 
example, there is only a single service option at stage 1, 
namely, outpatient services assigned at entry. In stage 2, 
there are two services options: discontinue outpatient or 
switch to intensive outpatient treatment. There are no 
tailoring variables at stage 1, while the tailoring variable 
at stage 2 is “responder status” during months 0–3 (e.g., 
abstinent or not during months 0–3). More complex AIs 
may include more than two stages, intervention options 
at each stage, and tailoring variables.
Although there is research related to AIs for SUD 
treatment [15, 28–31], we are unaware of any research 
on recommendations for the setting of adolescent sub-
stance use treatment. The American Society of Addiction 
Medicine (ASAM) Criteria [32] are a major step forward 
in comprehensive, individualized treatment planning, 
although the research foundations for the ASAM Cri-
teria are based largely on adult data [33–40]. Additional 
research is needed to generate hypotheses about, and to 
better understand the utility of proposed AIs, for ado-
lescents. This project aims to develop and evaluate AIs 
that begin to provide much-needed empirical evidence 
addressing important questions such as: What tailor-
ing variables and outcomes should be considered when 
deciding an adolescent’s treatment setting? What values 
on these tailoring variables signify response versus non-
response? Are there any combinations of initial and sub-
sequent treatment setting that work synergistically or 
antagonistically?
Methods for developing AIs using observational, 
practice‑based data
There are several methods for making causal inferences 
about the effects of AIs that could be applied to obser-
vational, practice-based data [41, 42]. However, there 
have been few applications of such methods to com-
plex, practice-based observational datasets relevant to 
adolescent SUDs. We suspect that methods available to 
Fig. 1 Example of a 6-month, two-stage service-level adaptive inter-
vention (AI) for adolescent marijuana users
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identify AIs have not been readily adopted to observa-
tional data analyses in adolescent SUD in part due to a 
lack of theory and conceptual models to guide the devel-
opment of AIs [54]. As such, the current study relies on 
a mixed methods approach using stakeholder engage-
ment to compliment statistical methods used to inform 
the identification of potentially meaningful AIs. In addi-
tion, an empirical study of the causal effects of AIs using 
observational study data particularly requires careful 
consideration of the potential impact of time-varying 
confounding bias [43–50]. In the sequential decision-
making setting, confounders of the effect of subsequent 
treatment are often also outcomes of previous treatment. 
In such settings, the use of standard regression, or even 
naïve use of standard propensity score adjustments, may 
actually cause more bias [51–53]. Appropriate and robust 
inverse-probability-of-treatment weighting methods can 
account for such confounders.
Objectives
This study protocol describes a project to begin the devel-
opment of AIs for the settings of adolescent substance 
use treatment, based on adolescents’ evolving individual 
needs throughout the clinical pathway. This project has 
three discrete aims. First, we aim to explore the views 
of various stakeholders (parents, providers, policymak-
ers, and researchers) on important factors to consider 
when deciding the setting of substance use treatment 
for adolescents. Second, we aim to generate hypoth-
eses concerning candidate AIs via statistical analyses of 
observational, practice-based empirical data from ado-
lescent substance use treatment settings and informed by 
our examination of stakeholder views. Third, we aim to 
compare the relative effectiveness among candidate AIs 
as well as non-adaptive interventions that are commonly 
used in everyday practice. The empirically-informed AIs 
we aim to produce can help guide future placement of 
adolescents with SUDs into the most appropriate treat-
ment settings at the most appropriate times for their 
individual needs, as well as lay the foundations for future 
randomized trials to more rigorously evaluate or identify 
effective AIs [23, 55–63].
Methods
Global Appraisal of Individual Needs
The current project will utilize longitudinal observational 
data on 15,696 unique adolescents who were adminis-
tered the Global Appraisal of Individual Needs (GAIN) 
[64]. The GAIN has eight sections assessing background 
and demographic characteristics, substance use, physi-
cal health, mental health, risk behaviors, environmental, 
legal, and educational/vocational problem areas. Within 
each problem area, items assess problem characteristics, 
recency, severity, and service utilization. As such, use of 
longitudinal GAIN data provides the current study with 
an opportunity to identify and assess the relative effec-
tiveness of candidate AIs. The data was routinely col-
lected by Center for Substance Abuse Treatment (CSAT) 
discretionary grantees engaged in adolescent substance 
use program activities between 1997 and 2012. During 
this time, recipients of CSAT discretionary grants for 
adolescent substance use treatment research collected 
data on their clients using the GAIN. Adolescents were 
surveyed at four time points over the course of a year 
(namely, at intake and at 3-, 6-, and 12-months post-
intake). Gender and race distributions closely mirrored 
those found in adolescent treatment samples nationally: 
namely, 74% of admissions were male, 18% were non-His-
panic African American, and 35% were Hispanic/Latino. 
It is important to note that this dataset is not necessarily 
representative of all adolescent substance use treatment 
facilities operating today—we suspect these are better 
performing facilities [65]. However, in the absence of 
such a large nationally-representative dataset, this one is 
uniquely poised to address our project aims.
Aim 1. Identify key components of feasible AIs
Objectives
The first aim of this project is to examine the views of 
stakeholders (parents, clinicians, researchers, policy-
makers) on which tailoring variables and outcomes are 
most important to consider when deciding the setting 
of substance use treatment for adolescents. This aim will 
be used to inform the empirical data analyses for the 
remaining project aims.
Online Delphi process
Using an online system called ExpertLens [66], we will 
conduct an online Delphi process [67] in which we will 
ask stakeholders to rate the importance of individual 
needs contained within the GAIN as potential tailoring 
variables for treatment or key outcomes of interest. We 
will organize these individual needs according to the six 
dimensions of the ASAM Criteria: (1) acute intoxication 
and withdrawal potential; (2) biomedical conditions and 
complications; (3) emotional/behavioral/cognitive con-
ditions and complications; (4) readiness to change; (5) 
relapse, continued use, or continued problem potential; 
and (6) recovery/living environment. We will also ask 
participants to rate the importance of clinical outcomes 
based on the National Outcome Measures (NOMs) from 
the Substance Abuse and Mental Health Services Admin-
istration (SAMHSA) [68].
Potential participants will be identified by first con-
structing a list based on published research, suggestions 
from known stakeholders in this area, and member lists 
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of relevant societies and organizations. This will be fol-
lowed by “snowball sampling” in which stakeholders can 
nominate further participants. To be eligible, participants 
must identify with one of the following four stakeholder 
groups: (1) parents of adolescents who have received 
substance use treatment; (2) providers of adolescent 
substance use treatment; (3) professionals involved in 
program planning at the clinic, health-system, state, or 
federal levels; or (4) researchers of adolescent substance 
use treatment. We aim to recruit at least 20–40 partici-
pants per stakeholder group. To improve recruitment 
and retention, participants will receive a $200 gift card 
for completing the process.
Our Delphi process will involve two separate rating 
rounds, with a round of online group discussion and 
feedback in between. We expect to keep each round 
open for 7–10  days and for each round to take partici-
pants about 1 h to complete. In Round One, participants 
will use a 9-point Likert scale to rate the importance of 
assessing each need or goal for deciding the appropriate 
setting (outpatient, intensive outpatient, residential, or 
inpatient) for an adolescent’s substance use treatment. 
A rating of 1 will correspond to “of lower importance” 
and a rating of 9 to “of higher importance.” Participants 
will also be able to comment on the rationale underpin-
ning their ratings as well as suggest additional individual 
needs and treatment goals to rate in Round Three.
In Round Two, participants will see graphed results 
from Round One—including the median and frequen-
cies for each item—as well as how a participant’s own rat-
ing compares to group ratings. They will also be shown 
decisions about the group’s agreement or disagreement 
on the importance of items for the checklist, as deter-
mined by the inter-percentile range adjusted for symme-
try (IPRAS) analysis technique from the RAND/UCLA 
Appropriateness method [69]. If an item has disagree-
ment, it is considered to have uncertain importance. If 
an item has agreement, the tertile in which the median 
rating for importance falls will be analyzed: a median 
score between 1 and 3 will indicate lower importance, 4 
and 6 will indicate moderate importance, and 7 and 9 will 
indicate higher importance. These determinations will be 
summarized in user-friendly, color-coded text beneath 
each graph: green text indicating the group agreed the 
item has higher importance; yellow text, that the item 
has moderate importance; and red text, that the item 
has lower importance. Participant comments on each 
item from Round One will also be provided so partici-
pants can understand others’ rationales for their ratings. 
Participants will be asked to discuss these results in an 
anonymous online discussion forum to explore areas of 
agreement and disagreement. Rather than having partici-
pants sign in simultaneously, they post comments at their 
own leisure at times convenient to their schedules to 
increase engagement in discussion while preventing par-
ticipant fatigue. Project team members will moderate all 
panels to promote participant engagement in discussions.
In Round Three, participants will re-rate each item in 
light of Round Two discussions of Round One results, as 
well as rate new items participants may have proposed 
in Round One. The process allows participants to revise 
their views and identify items they deem most impor-
tant for the checklist. On the last page of the Round 
Three questionnaire, participants will be asked to provide 
input on the ExpertLens process. Participant anonym-
ity of responses will be ensured via use of usernames in 
the ExpertLens system (e.g., Participant 1, Participant 
2, etc.). Individual responses will be known only to the 
ExpertLens moderators.
Upon completion of the Delphi process, a descrip-
tive analysis of participant ratings will characterize the 
distribution of group responses from each round, esti-
mate changes in group responses between rounds, and 
determine areas of agreement and disagreement. Those 
items reaching consensus for high importance (using the 
IPRAS method) in Round Three will be prioritized for 
inclusion in the decision rules to be developed and evalu-
ated in later project stages. To interpret these ratings, a 
thematic analysis will be conducted by systematically 
coding all comments linked to each of the items, indexing 
codes into preliminary and inductively identified themes, 
charting and integrating themes across items, and relabe-
ling the final themes as appropriate [70].
Aim 2. Empirically identify high‑quality candidate AIs
Objective
The second aim of this project is to generate hypotheses 
about candidate AIs for deciding the setting for an ado-
lescent’s substance use treatment using practice-based 
observational data on the GAIN from the CSAT dataset 
[64]. The development of candidate AIs will be informed 
by our stakeholder engagement and will consist of rec-
ommendations at two decision points: 0–3 months (stage 
1 decision) and 3–6 months (stage 2 decision).
Settings of adolescent substance use treatment
The two stages of treatment (0–3 and 3–6  months) were 
determined by the GAIN observational study data collec-
tion protocol. For decisions about adolescent substance use 
treatment settings (i.e., residential vs. outpatient vs. inten-
sive outpatient treatment), the 3-month time interval in the 
CSAT data is highly relevant, as participation in treatment 
services for at least 90 days is generally regarded as a best 
practice [6, 8, 71], and most evidence-based prevention/
treatment programs for substance use disorders among 
adolescents are an average of 12 weeks long [10, 16, 72].
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At each stage, there are four possible decisions regard-
ing treatment setting: outpatient, intensive outpatient, 
residential/inpatient, or no treatment. Outpatient set-
tings involve organized services for substance use that do 
not require an adolescent to be admitted to a residential 
program or hospital. Intensive outpatient settings require 
additional structure and support than regular outpatient 
services. Residential settings involve intensive, structured 
services for substance use that require an adolescent to 
be admitted but do not involve hospitalization. Inpa-
tient settings involve intensive, structured services for 
substance use that require 24-h care in a safe and secure 
hospital unit. In our dataset, outpatient settings are the 
most common (see Table 1). In this study, inpatient and 
residential treatment settings are combined because they 
are asked about jointly in the GAIN survey.
Adolescent participation in a treatment setting dur-
ing each 90-day period (“stage”) will be assessed using a 
combination of treatment log data and adolescents’ self-
reports of treatment experiences in the 90 days prior to 
a follow-up visit. Our treatment measures group ado-
lescents into the four specific treatment settings based 
on whether or not an adolescent received any amount 
of treatment in the specific setting during the 90-day 
period in question. For example, to be in the residential 
group, an adolescent only needs to have received treat-
ment in a residential setting for at least 1 day during the 
past 90 days. Adolescents in the “no treatment” condition 
will be coded as such if they reported no days of treat-
ment received in outpatient, intensive outpatient, or resi-
dential/inpatient settings during the past 90 day period. 
We will also conduct sensitivity analyses assigning ado-
lescents to the treatment setting in which they spent the 
most days over the 90 day period.
Candidate tailoring and confounding variables
Overall, the GAIN contains over 1000 items and 
100-symptom count, change score, and service utiliza-
tion indices that could be used for defining AIs and for 
dealing with confounding adjustment over time [73]. 
Moreover, since the GAIN was developed to assist cli-
nicians with patient placement decisions, over 80 items 
were designed to operationalize the ASAM Criteria [74, 
75]. Given the structure of the GAIN, there are hundreds 
of candidate tailoring variables at baseline that can be 
used to make the stage 1 services decision. At stage 2, the 
same baseline variables—as well as change in these meas-
ures from baseline to the end of month 3 and treatment 
assigned during the first 3  months—form a large list of 
possible tailoring variables from which to choose. Conse-
quently, AIs generated from the GAIN have the possibil-
ity of being more individually-tailored than the template 
example provided in Fig. 1.
Outcomes
Outcomes of interest will be drawn from and informed 
by the set of “positive” measures selected by SAMHSA 
for the NOMs: i.e., no substance use, no SUD symptoms, 
no physical health problems, no mental health prob-
lems, no illegal activity, no justice system involvement, 
housed in the community, no family problems, vocation-
ally engaged, and socially supported [76]. Each NOM will 
be turned into a “positive” binary indicator, and the total 
count of the number of positively endorsed NOMs will 
be used as our primary outcome variable. In addition to 
using the overall count of binary indicators of NOMs, we 
will also carefully examine continuous versions of these 
outcomes.
Analytic plan
A number of state-of-the-art methods will be utilized to 
identify candidate AIs using the CSAT dataset as part 
of our Aim 2 efforts. All of the methods we propose to 
use are based on the principles of Q-learning (Q-L)—an 
idea borrowed from computer science that can be seen 
as an extension of moderated regression analysis to the 
sequential decision-making setting [18, 61]. Q-L uses a 
backward induction logic (dynamic programming [77]) 
that incorporates effects of future decisions in evaluating 
present decisions. This ensures that the constructed AIs 
optimize outcomes over the short- and long-term, rather 
than selecting the setting at each stage that improves 
outcomes only in the short-term and, therefore, ignores 
any potentially beneficial delayed effects of earlier deci-
sions. In the Q-L regression analyses, the goal will be to 
find AIs that maximize the mean number of positively 
endorsed NOMs (primary outcome) and continuous ver-
sions of individual NOMs (secondary outcomes). We will 
carefully compare and contrast the findings from various 
methods for implementing Q-L with our dataset. Please 
see Additional file 1 for a technical overview of Q-L.
Data partitioning and power
We will partition the CSAT dataset (N = 15,656) into two 
datasets, each of which is representative of all partici-
pants in the CSAT dataset. One dataset will be used for 
estimating AIs (Aim 2; e.g., our way to generate hypothe-
ses about specific candidate AIs that might prove promis-
ing for adolescents) and a second dataset will be used for 
Table 1 Number of youth in each treatment service
Time period Level of care grouped
OP IOP RES/IP
Between intake and 3-month 8518 1800 1743
Between 3 and 6-months 4898 1137 1225
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evaluation (see Aim 3 below). The purpose of data par-
titioning is to avoid “overfitting” by evaluating the iden-
tified AI with the same data used to empirically identify 
candidate AIs (Aim 2), a practice that may overstate the 
usefulness of an AI. Since Aims 2 and 3 will use mutu-
ally exclusive, random, subsamples of the complete CSAT 
dataset, power for both analyses is based on a raw sam-
ple size of approximately 7828 youth. Although a sam-
ple of 7828 youth is large, given the complexity of the AI 
estimation methods, it is difficult to judge the power of 
the analysis to identify meaningful tailoring variables or 
accurately distinguish among alternative treatment set-
tings. Hence, the value of identified AIs will be assessed 
through out-of-sample evaluation in Aim 3. For Aim 3, 
assuming (conservatively) that a minimum of 500 youth 
in the data provide information about the effectiveness 
of a particular AI, and that weighting (discussed below) 
reduces this sample to an effective sample size of 250, we 
will be able to detect differences that are at least as large 
as 13 percentage points for binary outcomes and 0.25 
effect sizes for continuous outcomes, assuming a two-
tailed hypothesis test and a type-I error of 0.05. Mean 
rates of missingness on items ranged from less than 1 
to 27.1%, with a mean of 13.4% across items at all of the 
follow-ups. Missingness will be dealt with explicitly by 
chained equations multiple imputation, [78], as imple-
mented in the R package mice [79].
Aim 3. Evaluate the relative effectiveness of candidate AIs
Objective
The third aim of this project is to evaluate the relative 
effectiveness of candidate AIs generated in Aim 2 by 
independently examining their causal effects on relevant 
clinical outcomes. In addition to comparing the relative 
effectiveness of candidate AIs with each other, we will 
also compare them against the following non-adaptive 
decision rules that are commonly used in everyday prac-
tice: (1) outpatient services for months 0–3 and then no 
treatment for months 0–6, (2) always outpatient services 
(i.e., outpatient for all months 0–6), (3) always intensive 
outpatient, (4) always residential\inpatient, and (5) no 
treatment for all months. As with Aim 2 analyses, the 
goal will be to find AIs most effective on the mean num-
ber of positively endorsed NOMs (primary outcome) 
and continuous versions of individual NOMs (secondary 
outcomes).
Analytic plan
To compare the relative effectiveness of candidate AIs 
against each other and non-adaptive decision rules, we 
will use marginal structural modeling (MSM): a class of 
causal longitudinal models for conceptualizing and esti-
mating the causal effects of time-varying treatments [43, 
80–84]. MSMs, when used together with “inverse-prob-
ability of treatment weighting” (IPT) [80, 83–86], can 
remove or greatly eliminate the bias that time-varying 
confounders contribute to estimates of the causal effects 
of the AIs. Estimated IPT weights for each of the ado-
lescents in the dataset at each decision stage reduce the 
compositional imbalance in the confounders among ado-
lescents who receive different sequences of treatments. 
We aim to generalize this analytic approach to allow for 
comparison between multiple AIs [87].
Discussion
This project aims to provide several innovative insights 
for the field of adolescent substance use treatment. First, 
despite the obvious need and early successful efforts 
toward treatment guidelines, little to no research is cur-
rently and explicitly devoted to the empirical construc-
tion of AIs for guiding the individualized selection of 
settings for adolescent substance use treatment. The field 
has recognized the need to move beyond research that 
informs how to match adolescents with SUDs to initial 
treatments (i.e., based solely on known baseline charac-
teristics of the adolescent at treatment entry) to research 
that informs how to adapt and re-adapt subsequent treat-
ment over time to the specific needs of the individual [15, 
19, 25]. The overarching scientific goal of this project is to 
begin the development of such guidance via the explicit 
development of empirically-based AIs. Second, stake-
holder input is a critical supplement to the development 
of AIs that are both effective and feasible in practice. 
Existing conceptual models or behavioral theories are by 
themselves informative yet insufficient for constructing 
the data analysis models needed to identify effective AIs. 
To our knowledge, this project will be the first to use a 
mixed-methods, iterative approach whereby input from 
providers, policy-makers, researchers, and parents will 
directly inform the statistical models used to learn about 
effective and realistic AIs. Lastly, we will extend and illus-
trate the use of modern statistical methods for construct-
ing and evaluating AIs using practice-based observational 
data. Methodologists have developed rigorous and effec-
tive methods such as Q-L, decision lists, and MSM for 
constructing and evaluating AIs from observational study 
data [43, 45, 88]. Despite the power, elegance, and avail-
ability of such methods, they are not routinely employed 
in adolescent substance use research.
We note several important considerations at the out-
set of this project. First, the robustness of findings from 
Aim 1 will depend on the stakeholders we are able to 
recruit for the panel and retain through the final rating 
round. Second, Aims 2 and 3 rely on data collected in 
the CSAT dataset, which provides rather coarse infor-
mation about the timing of treatments received during 
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a particular 90-day window. Because it is impossible to 
disentangle the order of treatment and outcomes within 
a given 90-day period in our dataset, finer-grained deci-
sion stages cannot be considered. Although it would have 
been ideal to have more detailed data on the timing of 
treatment receipt versus outcomes, we will appropriately 
lag our data to address this issue. In addition, we are lim-
ited in this study to the creation of AIs for assignment to 
different settings of treatment and cannot examine spe-
cific clinical interventions (e.g., cognitive behavioral ther-
apy, motivational enhancement therapy) received in these 
settings, based on the availability of data in the CSAT 
dataset. Lastly, given that this project uses observational 
rather than experimental data, results generated are bet-
ter viewed as hypothesis generating than confirmatory 
analyses. As such, this project represents an important 
first step in a process that itself will be adapted overtime.
In conclusion, this project will fill a major gap in ado-
lescent addiction science and clinical practice. It expands 
upon the use of multi-dimensional assessments for sub-
stance use treatment planning by creating sequential, 
individualized decision rules for the setting of adolescent 
substance use treatment—supported by both stakeholder 
input and statistical evidence. Results from this project 
could be used to inform the further development and 
revision of proposed multi-dimensional assessment and 
treatment planning tools in the field of substance use—
such as CONTINNUM, The ASAM Criteria Decision 
Engine™, and the GAIN Recommendation and Referral 
Summary). More immediately, identifying candidate AIs 
that have the promise of more effectively guiding deci-
sions to move adolescents between outpatient, intensive 
outpatient, residential, and inpatient settings will provide 
guidance to current practitioners and lay the foundation 
for subsequent experiments that can test candidate AIs in 
rigorous clinical trials.
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